Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma
K Kuroshima, H Yoshino, S Okamura… - Cancer …, 2020 - Wiley Online Library
Sunitinib, a multitargeted receptor tyrosine kinase inhibitor including vascular endothelial
growth factor, has been widely used as a first‐line treatment against metastatic renal cell …
growth factor, has been widely used as a first‐line treatment against metastatic renal cell …
Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma
K Kuroshima, H Yoshino, S Okamura… - Cancer …, 2020 - pubmed.ncbi.nlm.nih.gov
Sunitinib, a multitargeted receptor tyrosine kinase inhibitor including vascular endothelial
growth factor, has been widely used as a first-line treatment against metastatic renal cell …
growth factor, has been widely used as a first-line treatment against metastatic renal cell …
Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
K Kuroshima, H Yoshino, S Okamura, M Tsuruda… - Cancer …, 2020 - europepmc.org
Sunitinib, a multitargeted receptor tyrosine kinase inhibitor including vascular endothelial
growth factor, has been widely used as a first‐line treatment against metastatic renal cell …
growth factor, has been widely used as a first‐line treatment against metastatic renal cell …
Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma
K Kuroshima, H Yoshino, S Okamura, M Tsuruda… - Cancer Science, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Sunitinib, a multitargeted receptor tyrosine
kinase inhibitor including vascular endothelial growth factor, has been widely used as a first …
kinase inhibitor including vascular endothelial growth factor, has been widely used as a first …
[HTML][HTML] Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma
K Kuroshima, H Yoshino, S Okamura, M Tsuruda… - Cancer …, 2020 - ncbi.nlm.nih.gov
Sunitinib, a multitargeted receptor tyrosine kinase inhibitor including vascular endothelial
growth factor, has been widely used as a first‐line treatment against metastatic renal cell …
growth factor, has been widely used as a first‐line treatment against metastatic renal cell …
Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma
K Kuroshima, H Yoshino, S Okamura… - Cancer …, 2020 - search.proquest.com
Sunitinib, a multitargeted receptor tyrosine kinase inhibitor including vascular endothelial
growth factor, has been widely used as a first-line treatment against metastatic renal cell …
growth factor, has been widely used as a first-line treatment against metastatic renal cell …
Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma
K Kuroshima, H Yoshino, S Okamura… - Cancer …, 2020 - search.proquest.com
Sunitinib, a multitargeted receptor tyrosine kinase inhibitor including vascular endothelial
growth factor, has been widely used as a first‐line treatment against metastatic renal cell …
growth factor, has been widely used as a first‐line treatment against metastatic renal cell …